Publications
Publications published since 2000 from OUS - Department of Gynaecological Oncology
396 publications found
Publications 2020
-
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139 -
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Int J Gynecol Cancer, 30 (12), 1997-2001
DOI 10.1136/ijgc-2020-001572, PubMed 32606097 -
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004 -
Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study
Int J Mol Sci, 21 (19)
DOI 10.3390/ijms21197288, PubMed 33023154 -
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
Int J Gynecol Cancer, 30 (9), 1444-1449
DOI 10.1136/ijgc-2020-001528, PubMed 32586892 -
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123838, PubMed 33352679 -
Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
EPMA J, 11 (2), 261-287
DOI 10.1007/s13167-020-00210-5, PubMed 32547652 -
Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
BMJ Support Palliat Care (in press)
DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506 -
Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2020-002176, PubMed 33361458 -
Systematic treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 30 1, 15 -
Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
Acta Oncol, 59 (6), 636-643
DOI 10.1080/0284186X.2020.1744717, PubMed 32238040 -
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
Radiat Oncol, 15 (1), 79
DOI 10.1186/s13014-020-01526-2, PubMed 32293487 -
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Gynecol Oncol, 159 (2), 442-448
DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695 -
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
J Clin Oncol, 38 (32), 3753-3762
DOI 10.1200/JCO.20.01164, PubMed 32822286 -
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
Int J Gynecol Cancer, 30 (11), 1748-1756
DOI 10.1136/ijgc-2020-001403, PubMed 32784203 -
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
JAMA Netw Open, 3 (1), e1918939
DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558 -
COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
Int J Gynecol Cancer, 30 (5), 561-563
DOI 10.1136/ijgc-2020-001419, PubMed 32221023 -
International Gynecologic Cancer Society 2019 meeting summary
Int J Gynecol Cancer, 30 (2), 167-173
DOI 10.1136/ijgc-2019-001146, PubMed 32029483 -
Base rate of ovarian cancer on algorithms in patients with a pelvic mass
Int J Gynecol Cancer, 30 (11), 1775-1779
DOI 10.1136/ijgc-2020-001416, PubMed 32699016 -
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385 -
The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
J Cancer Res Clin Oncol, 146 (12), 3137-3154
DOI 10.1007/s00432-020-03424-2, PubMed 33063131 -
Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
EPMA J, 11 (3), 377-398
DOI 10.1007/s13167-020-00217-y, PubMed 32843908 -
Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
Clin Breast Cancer, 20 (6), e711-e722
DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225 -
Preferences for follow up in long-term survivors after cervical cancer
Acta Obstet Gynecol Scand, 99 (9), 1253-1259
DOI 10.1111/aogs.13855, PubMed 32232835 -
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
Cancers (Basel), 12 (5)
DOI 10.3390/cancers12051292, PubMed 32443784 -
Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
Int J Mol Sci, 21 (21)
DOI 10.3390/ijms21217988, PubMed 33121141
Publications 2019
-
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Clin Cancer Res, 25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134 -
Endometrial cancer during pregnancy: management strategies
Int J Gynecol Cancer, 29 (7), 1221-1224
DOI 10.1136/ijgc-2019-000756, PubMed 31434687 -
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Gynecol Oncol, 152 (3), 560-567
DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768 -
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
Neoplasia, 21 (4), 353-362
DOI 10.1016/j.neo.2019.01.002, PubMed 30856376 -
Summary of landmark papers published between August 2018 and May 2019
Int. J. Gynecol. Cancer, 29 1, 1-5 -
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
Acta Oncol, 58 (6), 828-837
DOI 10.1080/0284186X.2019.1580386, PubMed 30810443 -
Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
Transl Oncol, 12 (3), 576-584
DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934 -
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Int J Gynecol Cancer, 29 (1), 181-187
DOI 10.1136/ijgc-2018-000021, PubMed 30640702 -
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Cochrane Database Syst Rev (10), CD012160
DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998 -
Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
Obstet. Gynecol. Surv., 74 (3), 156-158
Publications 2018
-
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
Gynecol Oncol, 152 (1), 53-60
DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719 -
Chromatin organisation and cancer prognosis: a pan-cancer study
Lancet Oncol, 19 (3), 356-369
DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 28 4, 29 -
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Cancer Chemother Pharmacol, 83 (1), 97-105
DOI 10.1007/s00280-018-3706-5, PubMed 30368585 -
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Gynecol Oncol, 150 (2), 239-246
DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697 -
PREFACE
Int. J. Gynecol. Cancer, 28 4, 2 -
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712 -
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
J Natl Cancer Inst, 110 (12), 1400-1408
DOI 10.1093/jnci/djy063, PubMed 29684152 -
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
Acta Oncol, 57 (8), 1100-1108
DOI 10.1080/0284186X.2018.1440085, PubMed 29451070 -
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790 -
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455 -
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161 -
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149
Publications 2017
-
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905 -
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014 -
A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
Int J Gynecol Cancer, 27 (4), 743-747
DOI 10.1097/IGC.0000000000000959, PubMed 28375931 -
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999 -
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432 -
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Am J Surg Pathol, 41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181 -
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
DOI 10.1111/aogs.13120, PubMed 28236297 -
Characteristics of tumor cell DNA affect prognosis
Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523 -
[Properties of cancer cell DNA affects the prognosis]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.16.0966, PubMed 29043733 -
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630 -
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323 -
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237 -
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497 -
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
Acta Oncol, 56 (5), 675-681
DOI 10.1080/0284186X.2017.1294762, PubMed 28447564 -
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187 -
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122 -
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Eur J Surg Oncol, 45 (1), 67-74
DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961 -
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
Gynecol Oncol, 145 (1), 148-153
DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195 -
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395 -
A study of chronic fatigue in Norwegian cervical cancer survivors
Gynecol Oncol, 146 (3), 630-635
DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254 -
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
Acta Obstet Gynecol Scand, 96 (10), 1162-1169
DOI 10.1111/aogs.13199, PubMed 28795770 -
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875 -
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713 -
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096
Publications 2016
-
Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
Obstet Gynecol, 128 (6), 1265-1273
DOI 10.1097/AOG.0000000000001777, PubMed 27824756 -
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024 -
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
DOI 10.1371/journal.pone.0156259, PubMed 27244197 -
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812 -
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771 -
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035 -
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Gynecol Oncol, 140 (3), 457-62
DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488 -
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
PLoS One, 11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508 -
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43 -
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8 -
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
DOI 10.1093/annonc/mdw238, PubMed 27407100 -
Preface
Int. J. Gynecol. Cancer, 26 1, 2 -
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73 -
Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
BMJ Open, 6 (11), e013728
DOI 10.1136/bmjopen-2016-013728, PubMed 28186949 -
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
Oncologist, 21 (6), 745-54
DOI 10.1634/theoncologist.2015-0239, PubMed 27009938 -
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
DOI 10.1056/NEJMoa1611310, PubMed 27717299 -
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471 -
Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
Eur J Surg Oncol, 42 (4), 513-22
DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445 -
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577 -
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723 -
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555 -
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585 -
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Ann Oncol, 27 (9), 1733-9
DOI 10.1093/annonc/mdw236, PubMed 27287207 -
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11 -
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Br J Cancer, 115 (2), 228-35
DOI 10.1038/bjc.2016.194, PubMed 27351218
Publications 2015
-
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914 -
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896 -
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230 -
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol, 17 (1), 78-89
DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673 -
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350 -
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
DOI 10.1080/15592294.2015.1085140, PubMed 26291246 -
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365 -
The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
ESC Heart Fail, 2 (3), 142-149
DOI 10.1002/ehf2.12048, PubMed 28834675 -
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338 -
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687 -
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncol, 16 (8), 928-36
DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797 -
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
Radiother Oncol, 117 (2), 333-7
DOI 10.1016/j.radonc.2015.09.014, PubMed 26372344 -
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Eur J Cancer, 51 (7), 825-32
DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433 -
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652 -
Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
Eur J Epidemiol, 31 (1), 95-8
DOI 10.1007/s10654-015-0033-6, PubMed 25903163
Publications 2014
-
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
DOI 10.1097/IGC.0000000000000205, PubMed 25033257 -
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994 -
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216 -
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803 -
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785 -
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546 -
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
Int J Gynecol Cancer, 24 (9 Suppl 3), S78-82
DOI 10.1097/IGC.0000000000000239, PubMed 25341585 -
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501 -
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303 -
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853 -
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194 -
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521 -
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
Cytometry A, 87 (4), 315-25
DOI 10.1002/cyto.a.22601, PubMed 25483227 -
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
J Clin Oncol, 32 (13), 1302-8
DOI 10.1200/JCO.2013.51.4489, PubMed 24637997 -
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S83-9
DOI 10.1097/IGC.0000000000000264, PubMed 25341586 -
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290 -
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323 -
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
Eur J Cancer, 50 (11), 1942-50
DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045 -
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159 -
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085 -
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027 -
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
BMC Cancer, 14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620 -
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701
Publications 2013
-
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
Radiother Oncol, 107 (1), 117-22
DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024 -
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714 -
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum Pathol, 45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798 -
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953 -
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
Gynecol Oncol, 131 (2), 437-44
DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107 -
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
J Pathol, 230 (1), 59-69
DOI 10.1002/path.4168, PubMed 23335387 -
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546 -
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518 -
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Lancet Oncol, 14 (3), 236-43
DOI 10.1016/S1470-2045(12)70567-3, PubMed 23333117 -
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671 -
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum Pathol, 44 (12), 2677-83
DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004 -
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Publications 2012
-
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
DOI 10.1186/1471-2407-12-454, PubMed 23039163 -
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560 -
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Gynecol Oncol, 128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314 -
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104 -
ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
PLoS One, 7 (9), e46317
DOI 10.1371/journal.pone.0046317, PubMed 23029477 -
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605 -
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
Ann Surg Oncol, 20 (4), 1348-54
DOI 10.1245/s10434-012-2673-z, PubMed 23054114 -
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Clin Cancer Res, 18 (11), 3197-206
DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981 -
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239 -
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403 -
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409 -
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154 -
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921 -
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637 -
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411 -
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
Ann Oncol, 24 (4), 937-43
DOI 10.1093/annonc/mds538, PubMed 23104722 -
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-2619
DOI 10.1093/annonc/mds060, PubMed 22539562 -
Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
Gynecol Obstet Invest, 75 (1), 61-7
DOI 10.1159/000345072, PubMed 23220872 -
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
Anal Cell Pathol (Amst), 35 (4), 305-14
DOI 10.3233/ACP-2012-0065, PubMed 22596183 -
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999 -
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
DOI 10.3109/0284186X.2012.689111, PubMed 22793037 -
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201 -
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906 -
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351 -
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
DOI 10.1038/bjc.2012.307, PubMed 22836511 -
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
Int J Mol Sci, 13 (10), 12925-38
DOI 10.3390/ijms131012925, PubMed 23202930
Publications 2011
-
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954 -
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668 -
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113 -
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924 -
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111 -
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
DOI 10.1007/s11136-011-0053-y, PubMed 22045155 -
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424 -
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542 -
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883 -
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
Mol Pharm, 8 (6), 2080-8
DOI 10.1021/mp200240a, PubMed 21761824 -
Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
Int J Gynecol Cancer, 21 (8), 1500-6
DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256 -
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
Radiother Oncol, 101 (1), 152-7
DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035 -
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
Clin Cancer Res, 17 (16), 5501-12
DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508 -
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408 -
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
Mol Oncol, 6 (1), 98-107
DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770 -
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
DOI 10.1002/cncr.26449, PubMed 22009736 -
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605 -
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Ann Oncol, 22 (11), 2417-2423
DOI 10.1093/annonc/mdr001, PubMed 21402619 -
The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
Eur J Gynaecol Oncol, 32 (4), 369-76
PubMed 21941955 -
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701 -
A phase 3 trial of bevacizumab in ovarian cancer
N Engl J Med, 365 (26), 2484-96
DOI 10.1056/NEJMoa1103799, PubMed 22204725 -
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-1184
DOI 10.1093/annonc/mdr368, PubMed 21965471 -
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Int J Gynecol Cancer, 21 (2), 419-23
DOI 10.1097/IGC.0b013e3182070f17, PubMed 21270624 -
Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
Gynecol Oncol, 121 (3), 600-4
DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294 -
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Ann Surg Oncol, 19 (2), 597-604
DOI 10.1245/s10434-011-1873-2, PubMed 21732142 -
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115 -
A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
J Cancer Surviv, 5 (2), 208-16
DOI 10.1007/s11764-011-0172-z, PubMed 21259075 -
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Br J Cancer, 105 (7), 890-6
DOI 10.1038/bjc.2011.328, PubMed 21878937
Publications 2010
-
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
Int J Gynecol Cancer, 20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029 -
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512 -
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol Histopathol, 25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439 -
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
J Clin Oncol, 28 (27), 4162-9
DOI 10.1200/JCO.2009.27.4696, PubMed 20733132 -
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
PLoS One, 5 (11), e13837
DOI 10.1371/journal.pone.0013837, PubMed 21079801 -
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin Exp Metastasis, 27 (3), 161-72
DOI 10.1007/s10585-010-9315-2, PubMed 20213325 -
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
Eur J Cancer, 46 (13), 2422-31
DOI 10.1016/j.ejca.2010.06.002, PubMed 20619634 -
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
Br J Cancer, 102 (6), 957-65
DOI 10.1038/sj.bjc.6605594, PubMed 20197765 -
Genomic aberrations in borderline ovarian tumors
J Transl Med, 8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781 -
Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
Genes Chromosomes Cancer, 49 (11), 1046-53
DOI 10.1002/gcc.20813, PubMed 20725991 -
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665 -
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
Am J Pathol, 177 (3), 1087-94
DOI 10.2353/ajpath.2010.100316, PubMed 20671266 -
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
Int J Gynecol Pathol, 29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853 -
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
BMC Cancer, 10, 493
DOI 10.1186/1471-2407-10-493, PubMed 20843305 -
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
J Clin Oncol, 28 (20), 3323-9
DOI 10.1200/JCO.2009.25.7519, PubMed 20498395 -
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Lancet, 376 (9747), 1155-63
DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993 -
Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
Int J Med Robot, 6 (2), 132-5
DOI 10.1002/rcs.295, PubMed 20049750 -
Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
Gynecol Oncol, 117 (2), 389; author reply 389-90
DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028 -
Management of cervical carcinoma stage IV: comment.
CME Journal of Gynecologic Oncology, 15 (1), 69-71
PublikaID 105 -
The treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 72-90
PublikaID 106 -
Surgery in treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 33-39
PublikaID 104 -
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med, 363 (10), 943-53
DOI 10.1056/NEJMoa0908806, PubMed 20818904 -
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
Eur J Cancer, 47 (1), 57-64
DOI 10.1016/j.ejca.2010.08.008, PubMed 20850296 -
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813 -
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
Diagn Cytopathol, 39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893
Publications 2009
-
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
Histopathology, 54 (3), 355-64
DOI 10.1111/j.1365-2559.2009.03231.x, PubMed 19236512 -
Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 20 Suppl 4, 29-31
DOI 10.1093/annonc/mdp120, PubMed 19454455 -
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
Hum Pathol, 40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507 -
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
Am J Clin Pathol, 132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818 -
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
Int J Gynecol Pathol, 28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938 -
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
Eur J Cancer, 45 (13), 2412-7
DOI 10.1016/j.ejca.2009.06.017, PubMed 19622417 -
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
PLoS Genet, 5 (11), e1000719
DOI 10.1371/journal.pgen.1000719, PubMed 19911042 -
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
BMC Cancer, 9, 2
DOI 10.1186/1471-2407-9-2, PubMed 19121203 -
Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
Int J Gynecol Cancer, 19 (4), 634-40
DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562 -
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
Gynecol Oncol, 113 (1), 128-33
DOI 10.1016/j.ygyno.2008.12.024, PubMed 19178933 -
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
Int J Gynecol Cancer, 19 (6), 1029-36
DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364 -
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
Virchows Arch, 454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773 -
Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity
Gynecol Oncol, 115 (1), 164-165
DOI 10.1016/j.ygyno.2009.05.028, PubMed 19539356 -
Robot-assisted laparoscopic surgery in gynaecological oncology; initial experience at Oslo Radium Hospital and 16 months follow-up
Int J Med Robot, 5 (4), 410-4
DOI 10.1002/rcs.272, PubMed 19569081 -
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396 -
[From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
DOI 10.4045/tidsskr.09.0067, PubMed 19337352 -
Ultrasound guidance for peripheral nerve blockade
Cochrane Database Syst Rev (4), CD006459
DOI 10.1002/14651858.CD006459.pub2, PubMed 19821368
Publications 2008
-
Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 19 Suppl 2, ii19-20
DOI 10.1093/annonc/mdn113, PubMed 18456753 -
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
Gynecol Oncol, 109 (3), 377-83
DOI 10.1016/j.ygyno.2008.02.025, PubMed 18407340 -
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
DOI 10.1136/jmg.2008.058248, PubMed 18413372 -
SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
Surg Oncol, 17 (3), 219-25
DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194 -
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990 -
Consistent numerical chromosome aberrations in thecofibromas of the ovary
Virchows Arch, 452 (3), 269-76
DOI 10.1007/s00428-007-0561-x, PubMed 18188592 -
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
Eur J Cancer, 45 (1), 82-9
DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092 -
Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
Eur J Gynaecol Oncol, 29 (6), 583-9
PubMed 19115683 -
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
Ann Oncol, 20 (2), 286-93
DOI 10.1093/annonc/mdn591, PubMed 18725390 -
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
DOI 10.1016/j.ijrobp.2007.12.030, PubMed 18355976 -
Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy
Int J Radiat Oncol Biol Phys, 73 (4), 1141-7
DOI 10.1016/j.ijrobp.2008.05.064, PubMed 18760883
Publications 2007
-
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
Hum Pathol, 38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728 -
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Mol Cancer, 6, 12
DOI 10.1186/1476-4598-6-12, PubMed 17274819 -
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 61 (1), 59-63
DOI 10.1136/jcp.2006.045864, PubMed 17468294 -
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
Gynecol Oncol, 108 (2), 348-54
DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925 -
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
J Clin Oncol, 25 (15), 2049-56
DOI 10.1200/JCO.2006.09.1769, PubMed 17513809 -
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
BMC Cancer, 7, 11
DOI 10.1186/1471-2407-7-11, PubMed 17233882 -
Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
Eur J Gynaecol Oncol, 28 (4), 256-62
PubMed 17713088 -
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213 -
Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases. The future is now?
Int J Med Robot, 3 (3), 224-8
DOI 10.1002/rcs.152, PubMed 17924449 -
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
J Clin Oncol, 25 (20), 2909-20
DOI 10.1200/JCO.2007.11.1013, PubMed 17617522 -
ESGO statement on cervical cancer vaccination
Int J Gynecol Cancer, 17 (6), 1183-5
DOI 10.1111/j.1525-1438.2007.01129.x, PubMed 17997794 -
Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
BJOG, 114 (9), 1150-8
DOI 10.1111/j.1471-0528.2007.01445.x, PubMed 17655733 -
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
DOI 10.1093/annonc/mdm134, PubMed 17488735 -
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
Epigenetics, 2 (4), 237-43
DOI 10.4161/epi.2.4.5406, PubMed 18281782 -
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
Mol Cancer, 6, 45
DOI 10.1186/1476-4598-6-45, PubMed 17623056
Publications 2006
-
An international perspective on surgical health care and education
J Am Coll Surg, 204 (1), 148-57
DOI 10.1016/j.jamcollsurg.2006.09.021, PubMed 17189123 -
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
DOI 10.1080/00313020600561526, PubMed 16680901 -
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408 -
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090 -
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
Gynecol Oncol, 104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350 -
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
Gynecol Oncol, 103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205 -
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am J Clin Pathol, 125 (3), 451-8
DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351 -
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
Virchows Arch, 449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425 -
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
Gynecol Oncol, 103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315 -
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 60 (10), 1086-91
DOI 10.1136/jcp.2006.041194, PubMed 17158642 -
Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
Histopathology, 49 (3), 311-2
DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980 -
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
Cancer Immunol Immunother, 55 (10), 1280-4
DOI 10.1007/s00262-006-0121-2, PubMed 16429314 -
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
J Clin Microbiol, 44 (4), 1310-7
DOI 10.1128/JCM.44.4.1310-1317.2006, PubMed 16597856 -
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
BMC Genomics, 7, 268
DOI 10.1186/1471-2164-7-268, PubMed 17054779 -
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
Clin Exp Immunol, 144 (1), 53-8
DOI 10.1111/j.1365-2249.2006.03031.x, PubMed 16542365 -
Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
Eur J Gynaecol Oncol, 27 (3), 209-14
PubMed 16800244 -
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277 -
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561 -
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
Mod Pathol, 19 (9), 1227-35
DOI 10.1038/modpathol.3800641, PubMed 16729014 -
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
Eur J Gynaecol Oncol, 27 (5), 513-8
PubMed 17139990 -
Primary surgery for ovarian cancer
Eur J Surg Oncol, 32 (8), 844-52
DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797 -
Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
Hum. Mutat., 27 (2), 209-210 -
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Gynecol Oncol, 102 (1), 15-21
DOI 10.1016/j.ygyno.2005.11.034, PubMed 16499955
Publications 2005
-
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
DOI 10.1002/gcc.20128, PubMed 15578687 -
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res, 65 (1), 331-7
PubMed 15665311 -
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
Gynecol Oncol, 96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578 -
Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
Am J Obstet Gynecol, 192 (1), 48-54
DOI 10.1016/j.ajog.2004.07.038, PubMed 15672002 -
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
Cancer, 103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334 -
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Gynecol Oncol, 99 (2), 278-86
DOI 10.1016/j.ygyno.2005.06.036, PubMed 16061279 -
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177 -
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
Eur J Cancer, 41 (8), 1127-34
DOI 10.1016/j.ejca.2005.01.022, PubMed 15911235 -
Cyclins D1, D3, E, and A in vulvar carcinoma patients
Gynecol Oncol, 97 (3), 733-9
DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358 -
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746 -
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317 -
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702 -
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
Diagn Cytopathol, 33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397 -
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759 -
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Proc Natl Acad Sci U S A, 102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393 -
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
Cancer, 103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177 -
Markers of apoptosis in stage IB squamous cervical carcinoma
J Clin Pathol, 58 (6), 590-4
DOI 10.1136/jcp.2004.021220, PubMed 15917408 -
Risk grouping in stage IB squamous cell cervical carcinoma
Gynecol Oncol, 99 (1), 106-12
DOI 10.1016/j.ygyno.2005.05.026, PubMed 16137752 -
Re: "P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma"
Gynecol Oncol, 98 (2), 335-6
DOI 10.1016/j.ygyno.2004.09.011, PubMed 16039312 -
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344 -
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507
Publications 2004
-
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943 -
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
Br J Cancer, 91 (10), 1829-34
DOI 10.1038/sj.bjc.6602199, PubMed 15477862 -
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056 -
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
Clin Exp Metastasis, 21 (3), 191-9
DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369 -
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
Lung Cancer, 44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380 -
Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
Anal Chem, 76 (15), 4406-9
DOI 10.1021/ac049788k, PubMed 15283579 -
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
Gynecol Oncol, 93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972 -
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
Cancer Genet Cytogenet, 155 (1), 25-32
DOI 10.1016/j.cancergencyto.2004.02.010, PubMed 15527899 -
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Gynecol Oncol, 95 (1), 37-45
DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108 -
Endometrial cancer: the management of high-risk disease
Curr Oncol Rep, 6 (6), 471-5
DOI 10.1007/s11912-004-0078-2, PubMed 15485617 -
Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature
Eur J Gynaecol Oncol, 25 (2), 239-41
PubMed 15032292 -
E-cadherin and catenins in early squamous cervical carcinoma
Gynecol Oncol, 94 (2), 521-7
DOI 10.1016/j.ygyno.2004.05.046, PubMed 15297198 -
Cyclins and proliferation markers in early squamous cervical carcinoma
Gynecol Oncol, 92 (1), 40-6
DOI 10.1016/j.ygyno.2003.10.022, PubMed 14751136 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
Gynecol. Oncol., 92 (2), 730 -
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384 -
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786 -
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
Pathol Oncol Res, 10 (4), 212-8
DOI 10.1007/BF03033763, PubMed 15619642 -
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
Gynecol Oncol, 94 (2), 312-9
DOI 10.1016/j.ygyno.2004.05.019, PubMed 15297167 -
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123
Publications 2003
-
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma
Cancer, 98 (9), 1880-9
DOI 10.1002/cncr.11727, PubMed 14584070 -
The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 163-8
DOI 10.1111/j.1525-1438.2003.13354.x, PubMed 14656274 -
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit - Reply
Lancet, 362 (9392), 1334 -
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793 -
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
Clin Exp Metastasis, 20 (2), 161-9
DOI 10.1023/a:1022696012668, PubMed 12705637 -
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393 -
A systematic overview of radiation therapy effects in uterine cancer (corpus uteri)
Acta Oncol, 42 (5-6), 557-61
DOI 10.1080/02841860310014417, PubMed 14596513 -
A systematic overview of radiation therapy effects in ovarian cancer
Acta Oncol, 42 (5-6), 562-6
DOI 10.1080/02841860310014426, PubMed 14596514 -
A systematic overview of radiation therapy effects in cervical cancer (cervix uteri)
Acta Oncol, 42 (5-6), 546-56
DOI 10.1080/02841860310014660, PubMed 14596512 -
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
Gynecol Oncol, 91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677 -
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 599-609
DOI 10.1023/a:1027340208536, PubMed 14669791 -
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
Hum Pathol, 34 (9), 946-9
DOI 10.1016/s0046-8177(03)00345-9, PubMed 14562293 -
Discussion: Metastasis and angiogenesis in epithelial ovarian cancer
Gynecol. Oncol., 88 (1), S37-S42 -
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
DOI 10.1093/annonc/mdg403, PubMed 14504048 -
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
Int J Gynecol Cancer, 13 Suppl 2, 172-7
DOI 10.1111/j.1525-1438.2003.13363.x, PubMed 14656276 -
X chromosome inactivation in cervical cancer patients
Cancer Genet Cytogenet, 146 (1), 73-6
DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700 -
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Lancet, 361 (9375), 2099-106
DOI 10.1016/s0140-6736(03)13718-x, PubMed 12826431 -
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas
Gastroenterology, 124 (1), 270-1
DOI 10.1053/gast.2003.50034, PubMed 12512062 -
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
Gynecol Oncol, 89 (1), 140-7
DOI 10.1016/s0090-8258(03)00010-6, PubMed 12694668 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
Gynecol. Oncol., 90 (1), 231
Publications 2002
-
Hormonal treatment of endometrial carcinoma
Expert Rev Anticancer Ther, 2 (1), 106-12
DOI 10.1586/14737140.2.1.106, PubMed 12113059 -
Irofulven (MGI Pharma)
Curr Opin Investig Drugs, 3 (10), 1517-26
PubMed 12431030 -
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
Gynecol Oncol, 87 (1), 71-6
DOI 10.1006/gyno.2002.6801, PubMed 12468345 -
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
Br J Cancer, 87 (1), 61-4
DOI 10.1038/sj.bjc.6600350, PubMed 12085257 -
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219 -
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077 -
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
Eur J Gynaecol Oncol, 23 (5), 383-9
PubMed 12440808 -
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
Int J Surg Pathol, 10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570 -
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer, 94 (3), 707-12
DOI 10.1002/cncr.10250, PubMed 11857303 -
Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
Eur J Gynaecol Oncol, 23 (2), 93-103
PubMed 12013120 -
[Mass screening against endometrial cancer?]
Tidsskr Nor Laegeforen, 122 (18), 1767
PubMed 12362684 -
[Laparoscopic surgery in endometrial carcinoma]
Tidsskr Nor Laegeforen, 122 (25), 2429
PubMed 12448107
Publications 2001
-
Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix
Cancer, 92 (9), 2471-83
DOI 10.1002/1097-0142(20011101)92:9<2471::aid-cncr1597>3.0.co;2-k, PubMed 11745305 -
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
J Clin Oncol, 19 (12), 2983-93
DOI 10.1200/JCO.2001.19.12.2983, PubMed 11408493 -
Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
Anal Cell Pathol, 23 (2), 45-9
DOI 10.1155/2001/521873, PubMed 11904459 -
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899 -
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863 -
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382 -
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079 -
Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer - Are we quantitating hypoxia change? Response
Int. J. Radiat. Oncol. Biol. Phys., 49 (1), 285-289 -
Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature
Int J Gynecol Cancer, 11 (4), 255-62
DOI 10.1046/j.1525-1438.2001.011004255.x, PubMed 11520362 -
Fertility preservation in gynecologic cancer
Acta Obstet Gynecol Scand, 80 (9), 794-802
DOI 10.1034/j.1600-0412.2001.080009794.x, PubMed 11531628 -
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778 -
Clear-cell and papillary serous cancer: treatment options
Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
DOI 10.1053/beog.2000.0187, PubMed 11476564
Publications 2000
-
Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990
Cancer, 89 (6), 1291-9
DOI 10.1002/1097-0142(20000915)89:6<1291::AID-CNCR14>3.3.CO;2-F, PubMed 11002225 -
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490 -
Carcinoma of the fallopian tube
Cancer, 89 (10), 2076-84
PubMed 11066048 -
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398 -
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863 -
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
DOI 10.1053/hupa.2000.9776, PubMed 11014575 -
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
Int J Cancer, 88 (2), 217-22
DOI 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i, PubMed 11004671 -
DNA copy number changes in malignant ovarian germ cell tumors
Cancer Res, 60 (11), 3025-30
PubMed 10850452 -
Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
Int J Radiat Oncol Biol Phys, 46 (4), 935-46
DOI 10.1016/s0360-3016(99)00497-6, PubMed 10705016 -
Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
Clin Cancer Res, 6 (3), 1104-12
PubMed 10741740 -
Controversies in surgical management of advanced ovarian cancer (stage III-IV)
Eur J Gynaecol Oncol, 21 (5), 449-60
PubMed 11198031 -
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
DOI 10.1006/gyno.1999.5699, PubMed 10684705 -
[Ovarian cancer screening of high risk groups]
Tidsskr Nor Laegeforen, 120 (18), 2191
PubMed 11006746 -
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
DOI 10.1023/a:1008399414923, PubMed 10811493 -
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer, 36 Suppl 4, S59-61
DOI 10.1016/s0959-8049(00)00228-8, PubMed 11056321 -
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide
Eur J Gynaecol Oncol, 21 (3), 255-9
PubMed 10949388 -
Surgery for borderline tumor of the ovary
Semin Surg Oncol, 19 (1), 69-75
DOI 10.1002/1098-2388(200007/08)19:1<69::aid-ssu11>3.0.co;2-e, PubMed 10883027 -
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
J Natl Cancer Inst, 92 (18), 1534-5
DOI 10.1093/jnci/92.18.1534, PubMed 10995813